Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7% - Should You Sell?

Key Points

• Cogent Biosciences shares fell 5.7% to about $39.16, with trading volume down 88% from the average session.
• Analyst sentiment remains broadly positive: the stock has a “Moderate Buy” consensus rating and a $45.90 average price target, despite one sell rating.
• The company reported a quarterly loss of $0.52 per share, beating estimates by $0.03, while several major institutional investors—including BlackRock and Deutsche Bank—recently initiated positions.

Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report)'s stock price traded down 5.7% during trading on Tuesday . The stock traded as low as $39.58 and last traded at $39.1590. Approximately 275,811 shares were traded during trading, a decline of 88% from the average session volume of 2,222,771 shares. The stock had previously closed at $41.53.

Analyst Ratings Changes

Several equities analysts have recently weighed in on COGT shares. Weiss Ratings restated a "sell (d-)" rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Wedbush reissued an "outperform" rating and set a $55.00 price target on shares of Cogent Biosciences in a research report on Friday, May 29th. Finally, HC Wainwright raised their price target on Cogent Biosciences to $55.00 and gave the company a "buy" rating in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Cogent Biosciences has an average rating of "Moderate Buy" and a consensus target price of $45.90.

Cogent Biosciences Trading Down 5.7%

The company has a market cap of $6.69 billion, a price-to-earnings ratio of -18.02 and a beta of 0.38. The company has a current ratio of 15.14, a quick ratio of 15.14 and a debt-to-equity ratio of 0.41. The business's 50 day moving average price is $37.53 and its 200-day moving average price is $36.66.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.03. On average, equities analysts anticipate that Cogent Biosciences, Inc. will post -2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. E Fund Management Co. Ltd. bought a new position in shares of Cogent Biosciences during the second quarter worth approximately $500,000. BlackRock Inc. bought a new stake in shares of Cogent Biosciences in the second quarter valued at approximately $671,547,000. Deutsche Bank AG acquired a new stake in Cogent Biosciences during the second quarter worth approximately $10,317,000. TimesSquare Capital Management LLC acquired a new stake in Cogent Biosciences during the second quarter worth approximately $17,328,000. Finally, Persistent Asset Partners Ltd bought a new position in Cogent Biosciences during the 2nd quarter worth $5,351,000.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source